JYJiaao Yu

Jiaao Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiaao Yu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Jingchun Zhao

    Department of Burn Surgery, the First Hospital of Jilin University, Changchun, People’s Republic of China

    2 shared publications
  • Kai Shi

    Department of Burn Surgery, the First Hospital of Jilin University, Changchun, People’s Republic of China

    2 shared publications
  • Xinxin Chen

    Department of Burn Surgery, First Hospital of Jilin University, Changchun 130021, P.R. China

    2 shared publications
  • Xinxin Gao

    Department of Burns Surgery, The First Hospital of Jilin University, Changchun, China

    2 shared publications
  • Bo Wang

    Institute for Interdisciplinary Biomass Functional Materials Studies, Jilin Engineering Normal University, Changchun, China

    1 shared publication
  • Chaoliang He

    State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun People's Republic of China

    1 shared publication

Latest Publications

  • Stimulus-responsive hydrogels for diabetic wound management via microenvironment modulation

    by Yang Gao, Xinxin Chen, Chaoliang He, Zhen Zhang, Jiaao Yu

    This review highlights physical and biochemical signal-responsive hydrogels that dynamically remodel diabetic wound microenvironments to enable precision treatment.


  • Open Access

    Assessment between antiseptic and normal saline for negative pressure wound therapy with instillation and dwell time in diabetic foot infections

    by Jingchun Zhao, Kai Shi, Nan Zhang, Lei Hong, Jiaao Yu

    Negative pressure wound therapy with instillation and dwell time (NPWTi-d) is increasingly used for a diverse range of wounds. Meanwhile, the topical wound irrigation solution consisting of polyhexamethylene biguanide and betaine (PHMB-B) has shown efficacy in managing wound infections. However, the effectiveness of this solution as a topical instillation solution for NPWTi-d in patients with diabetic foot infections (DFIs) has not been thoroughly studied. The objective of this retrospective study was to evaluate the impact of using PHMB-B as the instillation solution during NPWTi-d on reducing bioburden and improving clinical outcomes in patients with DFIs. Between January 2017 and December 2022, a series of patients with DFIs received treatment with NPWTi-d, using either PHMB-B or normal saline as the instillation solution. Data collected retrospectively included demographic information, baseline wound characteristics, and treatment outcomes. The study included 61 patients in the PHMB-B group and 73 patients in the normal saline group, all diagnosed with DFIs. In comparison to patients treated with normal saline, patients with PHMB-B exhibited no significant differences in terms of wound bed preparation time (P = 0.5034), length of hospital stay (P = 0.6783), NPWTi-d application times (P = 0.1458), duration of systematic antimicrobial administration (P = 0.3567), or overall cost of hospitalization (P = 0.6713). The findings of the study suggest that the use of either PHMB-B or normal saline as an instillation solution in NPWTi-d for DFIs shows promise and effectiveness, yet no clinical distinction was observed between the two solutions.


  • Interferon-α2b-Induced RARRES3 Upregulation Inhibits Hypertrophic Scar Fibroblasts' Proliferation and Migration Through Wnt/β-Catenin Pathway Suppression

    by Xianglong Meng, Xinxin Gao, Kai Shi, Jingchun Zhao, Xiuhang Zhang, Xin Zhou, Xianjun Liu, Jiaao Yu

    Hypertrophic scar (HS) is a severe skin fibrotic disorder with unclear pathogenesis. Interferon-α2b (IFN-α2b) exerts inhibitory effects on HS in vivo and in vitro ; however, the exact mechanism remains unclear. In this study, we aimed to evaluate the inhibitory effects of IFN-α2b on hypertrophic scar fibroblasts' (HSFs) proliferation and migration, and to further investigate the associated molecular mechanism. Cell Counting Kit-8 and CyQUANT assays were used to assess HSFs' proliferation; wound healing and Transwell assays were used to assess HSFs' migration; real-time quantitative polymerase chain reaction and Western blotting were used to detect messenger RNA and protein levels, respectively, of related genes; bioinformatics analysis was performed to predict the downstream target of IFN-α2b. Our findings are as follows: (1) IFN-α2b inhibited HSFs' proliferation and migration in a dose-dependent manner. (2) IFN-α2b inhibited HSFs' proliferation and migration by suppressing the Wnt/β-catenin pathway. (3) Retinoic-acid receptor responder 3 (RARRES3) was predicted as a functional downstream molecule of IFN-α2b, which was low in HSFs. (4) IFN-α2b inhibited HSF phenotypes and the Wnt/β-catenin pathway by upregulating RARRES3 expression. (5) RARRES3 restrained HSFs' proliferation and migration by repressing the Wnt/β-catenin pathway. In conclusion, IFN-α2b-induced RARRES3 upregulation inhibited HSFs' proliferation and migration through Wnt/β-catenin pathway suppression.


  • Open Access

    Ellagic acid exerts anti-fibrotic effects on hypertrophic scar fibroblasts via inhibition of TGF-β1/Smad2/3 pathway

    by Xianjun Liu, Xinxin Gao, Hao Li, Zhandong Li, Xiaoe Wang, Li Zhang, Bo Wang, Xinxin Chen, Xianglong Meng, Jiaao Yu

    Hypertrophic scar (HS) is a kind of serious pathological scar with no currently effective treatment. HS fibroblasts (HSFs) are the main effector cells for HS formation. Ellagic acid (EA) exerts regulatory effects in some diseases, but its role in HS remains unclear. This study aimed to evaluate the effect of EA on the fibrotic phenotypes of HSFs and to further investigate the downstream signaling mechanism. The cell counting kit-8 (CCK-8) assay was used to perform cytotoxicity and proliferation assays. HSFs migration was assessed using wound healing and transwell assays. HSFs contraction was measured by a collagen lattice contraction assay and detection of α-smooth muscle actin (α-SMA) expression. The levels of mRNA and protein were determined by qPCR and western blotting, respectively. The results showed that EA inhibited the proliferation, migration, and contraction of HSFs and collagen expression in HSFs in a dose-dependent manner. Furthermore, EA not only suppressed the Smad2/3 pathway but also reversed TGF-β1-induced activation of the Smad2/3 pathway and up-regulation of the fibrotic cellular phenotypes in HSFs. These findings demonstrate that EA exerts anti-fibrotic effects on HSFs by blocking the TGF-β1/Smad2/3 pathway, which indicates that EA is a potential therapeutic candidate for treatment of HS.